文献速递主动脉疾病

胸主动脉腔内修复术后再次干预的现代特征与生存影响

Reinterventions in the modern era of thoracic endovascular aortic repair.
PubMed 文献 · J Vasc Surg · 2019-07-18

基于Vascular Quality Initiative 2010至2017年全国数据集,纳入7006例胸主动脉腔内修复(TEVAR)患者,分析再次干预的人群特征、时机及对生存的影响。结果显示553例(7.9%)至少接受一次再次干预,院内再次干预率3.5%;B型夹层再次干预率最高(11.5%),I型内漏为最常见原因;

要点

  • TEVAR术后再次干预不罕见,总体再次干预率7.9%,院内再次干预率3.5%。
  • B型夹层再次干预率最高(11.5%),I型内漏为各病种最常见原因。
  • 再次干预与未干预者生存无差异,但院内再次干预者死亡风险呈升高趋势。

核心结论

  • TEVAR术后再次干预并不少见,但再次干预组与未干预组死亡率无差异。
  • B型夹层患者TEVAR术后再次干预率最高,需重视疾病特异性随访模式。

研究设计与样本

  • 基于Vascular Quality Initiative全国数据集2010至2017年TEVAR患者的回顾性分析,共纳入7006例。
  • 采用t检验和χ2分析比较再次干预组与无再次干预组,Kaplan-Meier法分析免于再次干预率和生存率。

主要发现

  • 7006例中胸主动脉瘤占51.2%,B型夹层占33.5%,穿透性主动脉溃疡占7.0%,创伤占6.7%,壁内血肿占1.6%。
  • 553例(7.9%)至少接受一次再次干预,院内再次干预率为3.5%。
  • 各病种再次干预率:B型夹层11.5%,胸主动脉瘤6.7%,壁内血肿5.4%,穿透性主动脉溃疡4.8%,创伤1.8%。
  • 所有主动脉疾病中最常见的再次干预原因为I型内漏。
  • 长期再次干预方式最常见为置入腔内覆膜支架(65%),其次为其他手术治疗(15.9%)、其他腔内治疗(13%)、腔内分支治疗(12.4%)、未移除器械的手术治疗(11.0%)及手术分支治疗(10.4%)。

临床怎么用

  • TEVAR术后应进行长期随访,尤其B型夹层患者再次干预风险最高。
  • 随访中需重点关注I型内漏,因其为各病种再次干预的最常见原因。
  • 院内再次干预者死亡风险呈升高趋势,围术期需加强风险评估与监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Using a national data set, we sought to describe the population of patients and the nature and timing of reinterventions after thoracic endovascular aortic repair (TEVAR) by aortic disease as well as their impact on survival. METHODS: We evaluated the national data set for TEVAR in the Vascular Quality Initiative from 2010 to 2017. Student t-test and χ2 analysis were used to compare continuous and categorical variables in the reintervention and no reintervention groups, respectively. Freedom from reintervention and survival analysis was performed using Kaplan-Meier methods. RESULTS: A total of 7006 patients were evaluated: 51.2% thoracic aortic aneurysm, 33.5% type B dissection (TBD), 7.0% penetrating aortic ulcer, 6.7% trauma, and 1.6% intramural hematoma. Overall, 553 patients (7.9%) underwent at least one reintervention, with an in-hospital reintervention rate of 3.5%. Reinterventions were most commonly performed for TBD (11.5%), with reinterventions for other diseases occurring at lower rates: thoracic aortic aneurysm, 6.7%; intramural hematoma, 5.4%; penetrating aortic ulcer, 4.8%; and trauma, 1.8%. The most common cause of reintervention across all aortic diseases was type I endoleak. The most common long-term reinterventions were placement of endovascular stent graft (65%), other surgical treatments (15.9%), other endovascular treatment (13%), endovascular branch treatment (12.4%), surgical treatment with no device removal (11.0%), and surgical branch treatment (10.4%). Freedom from reintervention was decreased for TBD compared with other diseases (P < .001). There was no difference in survival comparing patients undergoing reinterventions and those without (P = .87). However, patients undergoing in-hospital reintervention trended toward increased mortality (P = .075). CONCLUSIONS: Whereas reinterventions were not rare after TEVAR, there was no difference in mortality between patients undergoing reintervention and those without. Patients undergoing TEVAR for TBD demonstrated the highest reintervention rate. This study highlights the importance of long-term follow-up to address disease-specific patterns of reintervention.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Fairman AS, Beck AW, Malas MB, et al. Reinterventions in the modern era of thoracic endovascular aortic repair. J Vasc Surg. 2019. PMID: 31327616. doi:10.1016/j.jvs.2019.04.484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。